The Technical AnalystExchange: SIX Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
PolyPeptide Group AG Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.49% CHF30.75
America/New_York / 2 mai 2024 @ 09:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 013.81 mill |
| EPS: | -1.530 |
| P/E: | -20.10 |
| Earnings Date: | Mar 12, 2024 |
| SharesOutstanding: | 32.97 mill |
| Avg Daily Volume: | 0.0644 mill |
| RATING 2024-05-02 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | n/a | n/a | |
| Asset | n/a | n/a | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -20.10 | sector: PE 27.19 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.74x |
| Company: PE -20.10 | industry: PE 27.19 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CHF-7.07 (-123.00%) CHF-37.82 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
CHF 29.52 - 31.98 ( +/- 4.00%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CHF30.75 (1.49% ) |
| Volume | 0.0088 mill |
| Avg. Vol. | 0.0644 mill |
| % of Avg. Vol | 13.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PPGN.SW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PPGN.SW
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.